Danish drugmaker Novo Nordisk and biotechnology company Vivtex Corp. announced Wednesday a partnership to develop next-generation oral biologic medicines for obesity, diabetes and associated comorbidities.
Vivtex is a pre-clinical drug development company that launched as a MIT spin off based on a proprietary platform developed in the laboratories of biotech legend Robert Langer in 2018.
Under the agreement, Vivtex will license select oral drug-delivery technologies to Novo Nordisk, while Vivtex is eligible to receive upfront consideration, research funding and milestone payments totalling up to 2.1 billion US dollars, and tiered royalties on future product sales.
The collaboration aims to enable the oral delivery of biologic drug candidates that are traditionally limited to injectable administration due to poor absorption in the gastrointestinal tract.
The partnership combines Novo Nordisk's deep expertise in peptide and protein therapeutics with Vivtex's proprietary gastrointestinal screening and formulation platform to identify next-generation oral therapeutics.
Vivtex's platform combines multiple proprietary gastrointestinal screening assays, drug-delivery technologies, and computational simulation and AI capabilities to optimize the oral delivery of biologic medicines. Novo Nordisk will assume responsibility for global development, regulatory activities, manufacturing, and commercialization of any resulting products.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.